Critical Illness
Conditions
Keywords
algorithm, tight glycemic control, glucose control, intensive care, insulin, ICU
Brief summary
Hyperglycemia is common in critically ill patients and associated with an adverse outcome. Thus, glycaemic control is an important issue in critical care. Despite extensive efforts of the intensive care unit staff difficulties were experienced in achieving efficient and safe glucose control. A fully automated algorithm may help to overcome some of these limitations by excluding intuitive interventions and integrating relevant clinical data in the decision-making process. Space GlucoseControl (TGC system) is a decision support system which helps to achieve safe and reliable blood glucose control in the desired ranges. Information on parenteral and enteral nutrition is automatically integrated into the calculations. The primary objective of the current study is to investigate the performance and usability of the Space TGC system for glucose control over an extended glucose control range (4.4 to 8.3 mmol/L) in postoperative cardiac surgery patients.
Interventions
DEVICESpace TGC
Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
Sponsors
B. Braun Melsungen AG
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Inclusion: * age: \> 18 years of age * admitted following cardiac surgery * stay in the ICU expected to be \> 20 h * blood glucose \> 6.7 mmol/l within 4 hours of ICU admission or patient already on insulin treatment Exclusion: * patients with hyperglycaemic crisis/ketoacidosis due to insulin deficiency. * known or suspected allergy to insulin * any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the patient (i.e., liver failure, other fatal organ failures) * patients participating in another study * moribund patients likely to die within 24 hours * patients after organ transplantation within the last three months * patients under high dose cortisol treatment (cortisol \> 1000 mg/day or equivalent doses of hydrocortisol)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (arterial) blood glucose values -> percentage of time within predefined glucose target range 4.4-8.3 mmol/dL | all blood glucose measurements from start of treatment until last glucose measurement under treatment (i.e. stop of intravenous insulin treatment) up to a maximum of 48h |
Secondary
| Measure | Time frame |
|---|---|
| Hypoglycaemia ≤ 40 md/dL (2.2mM) | all blood glucose measurements from start of treatment until last glucose measurement under treatment (i.e. stop of intravenous insulin treatment) up to a maximum of 48h |
| Usability parameters like convenience of alarming function; workload; blood sampling frequency | all blood glucose measurements from start of treatment until last glucose measurement under treatment (i.e. stop of intravenous insulin treatment) up to a maximum of 48h |
| Concomitant medication including insulin infusion rate, parenteral/enteral nutrition | all blood glucose measurements from start of treatment until last glucose measurement under treatment (i.e. stop of intravenous insulin treatment) up to a maximum of 48h |
Countries
United Kingdom
Outcome results
None listed